Stay informed about the latest diabetes news and research, including medical discoveries, treatment developments, clinical studies, technology and emerging health insights.
Eli Lilly’s experimental once-daily pill Foundayo, also known as orforglipron, demonstrates comparable heart safety to insulin glargine and superior glucose control, marking a potential breakthrough in oral diabetes treatments amid safety and tolerability considerations. Eli Lilly said its once-daily pill…
Eli Lilly’s experimental oral GLP-1 receptor agonist, orforglipron, has demonstrated comparable cardiovascular safety to insulin glargine while delivering superior blood-sugar reductions in a large clinical trial, potentially reshaping diabetes treatment options. Orforglipron, an oral GLP-1 drug being developed by Eli…
Research from Uganda indicates that adults over 40 on dolutegravir-based antiretroviral therapy face increased risks of hyperglycaemia, prompting calls for targeted glucose monitoring amidst expanding HIV treatment in Africa. In a retrospective cohort from Mbarara Regional Referral Hospital in southwestern…
Research suggests that insulin resistance may play a key role in Alzheimer’s development, sparking renewed interest in the metabolic links between diabetes and neurodegeneration despite the term ‘Type 3 diabetes’ remaining unofficial. Researchers are increasingly examining whether Alzheimer’s disease may…
Shares of Zealand Pharma dropped after new late-stage trial results for its experimental obesity drug, survodutide, highlighted tolerability issues despite promising efficacy in weight loss and blood sugar control. Zealand Pharma shares fell sharply on Thursday after new late-stage data…
Researchers at the University of Bath have developed innovative fluorescent molecular probes capable of tracking glucose changes within living animals, offering new insights into sugar metabolism and potential applications in disease diagnosis and treatment. Researchers at the University of Bath…
A new modelling study indicates that adopting England’s NHS diabetes prevention programme in Canada could slow the rise of type 2 diabetes and be cost-effective, especially with Indigenous-led adaptations in Ontario and Quebec. A publicly funded diabetes prevention programme modelled…
Research reveals that nearly one in six children aged 10 to 17 on GLP-1 drugs develop nutritional deficiencies within a year, urging better integration of dietary support into paediatric obesity and diabetes treatments. A new study in the journal Childhood…
As Milan hosts the 62nd European Association for the Study of Diabetes, Eli Lilly uses public initiatives, including a restored tram and pop-up installations, to make cardiometabolic health more accessible and connect medical advances with everyday life. As Milan prepares…
Wayne State University has secured a $5.7 million NIH grant to investigate why some lean individuals develop insulin resistance while some obese individuals remain sensitive, aiming to uncover new biological insights and therapeutic targets for type 2 diabetes. Wayne State…
A groundbreaking study demonstrates that children with newly diagnosed type 1 diabetes exhibit diverse biological signatures based on age at onset, suggesting the need for age-specific diagnostic and treatment approaches. Type 1 diabetes is increasingly being viewed as more than…
An experimental drug, retatrutide, has demonstrated significant weight loss and improved blood sugar control in mid-stage clinical trials, positioning it as a potential breakthrough in treating both obesity and type 2 diabetes. Experts caution against unregulated online sales as the…
